Biopsy Reclassification Risk in Prostate Cancer Examined
Gleason grade, prostate-specific antigen velocity, and imaging markers predict cancer spread.
Biopsy
Fewer Systematic Biopsy Cores May Not Lower PCa Detection Rate
In a study of patients undergoing transperineal prostate biopsy, the detection rate of clinically significant prostate cancer did not differ significantly between targeted biopsy (TB) with fewer systematic biopsy (SB) cores and TB with SB of the whole prostate.
Older Age Predicts Erectile Dysfunction After Transperineal Prostate Biopsy
Increased age was significantly associated with increased odds of a decline in Sexual Health Inventory for Men category, a study found.
Hospital Admissions for Prostate Biopsy Infections on the Rise
Although infection rates following prostate biopsy have stabilized, the rates of emergency department visits and hospitalizations for post-biopsy infections are increasing, a study found.
Prostate Cancer At Biopsy Linked to Low Natural Killer Cells
In a study, natural killer cell activity (NKA) below 200 pg/mL predicted a nearly 5-fold greater risk of having a positive prostate biopsy compared with higher NKA values.
Prostate Cancer Detection Greater With Targeted Plus Systematic Biopsy
In a study, combining targeted and systematic biopsy detected 11% to 33% more prostate cancers than either method alone.
Fluoroquinolones Tied to Increased Risk for Arrhythmia, CV Mortality
To investigate the risk of cardiovascular adverse effects associated with this antibiotic class, researchers conducted a systematic review, meta-analysis, and network meta-analysis using studies identified through a search of MEDLINE, EMBASE, and the Cochrane Library.
Prostate Biopsy Complications Deter Patients From Re-Biopsy
Study participants with acute urinary retention after TRUS-guided prostate biopsy were 4.5 times more likely to skip a recommended re-biopsy than men who had no initial biopsy-related complications.
Negative Confirmatory Biopsy Predicts Lower PCa Progression Risk
Men on active surveillance for prostate cancer who had a negative confirmatory biopsy experienced an 88% decreased risk of progression to treatment.
Fosfomycin Tops Fluoroquinolones for Prostate Biopsy Prophylaxis
In a meta-analysis, the risk of infectious complications was 78% lower with fosfomycin trometamol versus fluoroquinolones in men undergoing TRUS-guided prostate biopsy.
-
Loading...
-
Loading...
Next post in Prostate Cancer
